Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Amanta Healthcar
Quarter-by-quarter operating performance
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 68.10 | 66.73 | 67.81 | 72.06 | 65.31 | 70.89 | 74.49 | 76.99 |
| Expenses + | 54.70 | 52.85 | 52.75 | 53.10 | 50.41 | 56.24 | 59.13 | 62.03 |
| Operating Profit | 13.40 | 13.88 | 15.06 | 18.96 | 14.90 | 14.65 | 15.36 | 14.96 |
| OPM % | 19.68% | 20.80% | 22.21% | 26.31% | 22.81% | 20.67% | 20.62% | 19.43% |
| Other Income + | 0.15 | 0.21 | 0.87 | 0.16 | 0.96 | -2.56 | 0.68 | 1.66 |
| Interest | 9.45 | 6.32 | 5.90 | 6.28 | 6.29 | 5.15 | 5.06 | 4.25 |
| Depreciation | 4.60 | 4.60 | 4.51 | 4.69 | 4.64 | 4.66 | 4.67 | 4.75 |
| Profit before tax | -0.50 | 3.17 | 5.52 | 8.15 | 4.93 | 2.28 | 6.31 | 7.62 |
| Tax % | -28.00% | 28.71% | 22.64% | 26.87% | 28.80% | 46.93% | 26.47% | 27.43% |
| Net Profit + | -0.36 | 2.26 | 4.28 | 5.96 | 3.51 | 1.21 | 4.63 | 5.53 |
| EPS in Rs | -0.13 | 0.78 | 1.48 | 2.07 | 1.22 | 0.31 | 1.19 | 1.42 |
Financials of Amanta Healthcar
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 184 | 171 | 225 | 259 | 280 | 275 | 288 |
| Expenses + | 147 | 133 | 173 | 206 | 223 | 215 | 228 |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 | 60 |
| OPM % | 20% | 22% | 23% | 20% | 21% | 22% | 21% |
| Other Income + | 2 | 1 | 76 | 4 | 1 | 1 | 1 |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 21 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 | 19 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 | 21 |
| Tax % | 25% | 23% | 11% | 179% | 32% | 29% | 30% |
| Net Profit + | -19 | -22 | 55 | -2 | 4 | 10 | 15 |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Amanta Healthcar
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 29 | 39 |
| Reserves | 2 | -20 | 36 | 36 | 39 | 68 | 181 |
| Borrowings + | 231 | 235 | 226 | 216 | 211 | 204 | 244 |
| Other Liabilities + | 127 | 150 | 104 | 96 | 75 | 81 | 93 |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
| Fixed Assets + | 244 | 242 | 240 | 232 | 228 | 217 | 207 |
| CWIP | 0 | 0 | 0 | 9 | 0 | 7 | 82 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 | 7 |
| Other Assets + | 144 | 149 | 149 | 133 | 120 | 150 | 262 |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
Financials of Amanta Healthcar
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 38 | 31 | 62 | 43 | 58 | 47 | 48 |
| Cash from Investing Activity + | -9 | -13 | -6 | -7 | -10 | -24 | -94 |
| Cash from Financing Activity + | -37 | -18 | -50 | -42 | -46 | -23 | 126 |
| Net Cash Flow | -8 | -0 | 6 | -6 | 1 | -1 | 81 |
| Free Cash Flow | 27 | 19 | 52 | 36 | 46 | 26 | -32 |
| CFO/OP | 102% | 66% | 119% | 93% | 111% | 84% | 93% |
Financials of Amanta Healthcar
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 110 | 73 | 75 | 63 | 67 | 55 |
| Inventory Days | 225 | 422 | 338 | 247 | 309 | 464 | 312 |
| Days Payable | 99 | 186 | 185 | 130 | 129 | 194 | 136 |
| Cash Conversion Cycle | 229 | 345 | 226 | 193 | 243 | 336 | 231 |
| Working Capital Days | 51 | -5 | 28 | 42 | 16 | 26 | 6 |
| ROCE % | 9% | 14% | 13% | 14% | 15% | 12% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…